2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

monoclonal antibody (mAb)

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

1

Screening Libraries

1

Biochemical Assay Reagents

1

Peptides

40

Inhibitory Antibodies

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99941
    Retifanlimab

    		PD-1/PD-L1 Cancer
    Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
    Retifanlimab
  • HY-P9801
    Anti-Spike-RBD mAb
    1 Publications Verification

    SARS-CoV-2 (2019-nCoV) Spike RBD antibody

    		 SARS-CoV Infection
    Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of Spike protein and ACE2. Anti-Spike-RBD mAb is a potential therapeutic approach for SARS-CoV-2 treatment .
    Anti-Spike-RBD mAb
  • HY-P99383
    Volagidemab

    REMD-477; AMG-477

    		 GCGR Metabolic Disease
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) .
    Volagidemab
  • HY-P99113
    Inebilizumab
    1 Publications Verification

    		 ADC Antibody CD19 Inflammation/Immunology
    Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
    Inebilizumab
  • HY-P99825
    Relfovetmab

    		TNF Receptor Neurological Disease Inflammation/Immunology
    Relfovetmab is an anti-NGF monoclonal antibody (mAb) .
    Relfovetmab
  • HY-P99808
    Pulocimab

    		VEGFR Cancer
    Pulocimab is an anti-VEGFR2 monoclonal antibody (mAb). Pulocimab can be used for the research of cancers .
    Pulocimab
  • HY-163010
    Dicamba-propionic acid

    		Biochemical Assay Reagents Others
    Dicamba-propionic acid (DCa3) is a heterologous hapten that can be used to develop high-affinity monoclonal antibodies (mAb) against Dicamba. The Dicamba-propionic acid- developed mAb can be used to determine the residual amount of Dicamba in environmental water samples .
    Dicamba-propionic acid
  • HY-157257
    Trimethoprim fumaric acid

    		Biochemical Assay Reagents Others
    Trimethoprim fumaric acid (Compound CDI) is a universal hapten for ASGs (Antibacterial synergists) and can be used to design broadly specific monoclonal antibodies (mAbs) against ASGs. The mAb developed by Trimethoprim fumaric acid can be applied in ELISA to detect the residues of ASGs in foods of animal origin .
    Trimethoprim fumaric acid
  • HY-P99820
    Ranevetmab

    NV-01

    		 TNF Receptor Inflammation/Immunology
    Ranevetmab (NV-01) is a caninised anti-NGF monoclonal antibody (mAb). Ranevetmab can alleviate pain, and is used for the research of degenerative joint disease (DJD) pain .
    Ranevetmab
  • HY-P9802
    Anti-Spike-RBD Single Domain mAb

    SARS-CoV-2 (2019-nCoV) Single-Domain Antibodies; Humanized Single Domain antibody

    		 SARS-CoV Infection
    Anti-Spike-RBD Single Domain mAb is a CHO cell derived Alpaca monoclonal VHH-huFc antibody, specifically binds to SARS-CoV-2 RBD with high affinity .
    Anti-Spike-RBD Single Domain mAb
  • HY-P99589
    Sotevtamab

    16B5; AB-16B5

    		 Apoptosis Cancer
    Sotevtamab (16B5) is a humanized IgG2 anti-clusterin monoclonal antibody (mAb). Sotevtamab is an inhibitor of the epithelial to mesenchymal transition. Sotevtamab can be used for cancer research .
    Sotevtamab
  • HY-P9803
    Anti-SARS-80R mAb

    SARS-80R; SARS antibody-80R

    		 SARS-CoV Infection
    Anti-SARS-80R mAb (SARS-80R) is a human monoclonal IgG1 antibody produced in CHO cells. Anti-SARS-80R mAb can specifically bind to Spike (S1) protein to prevent SARS virus infection of susceptible cells .
    Anti-SARS-80R mAb
  • HY-P9805
    Anti-MERS-3A1 mAb

    MERS-3A1; MERS antibody-3A1

    		 SARS-CoV Infection
    Anti-MERS-3A1 mAb (MERS-3A1) is a human monoclonal IgG1 antibody with the high binding affinity produced in CHO cells. Anti-MERS-3A1 mAb bocks the binding of MERS-CoV spike protein to DPP4 receptor .
    Anti-MERS-3A1 mAb
  • HY-P99181
    Mupadolimab

    CPI-006

    		 CD73 Infection Inflammation/Immunology Cancer
    Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 POS B cells .
    Mupadolimab
  • HY-P99101
    Vobramitamab

    AEX-4089

    		 ADC Antibody Cancer
    Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. .
    Vobramitamab
  • HY-P99384
    Vofatamab

    B-701; MFGR-1877S; RG-7444

    		 FGFR Cancer
    Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC) .
    Vofatamab
  • HY-P9806
    Anti-MERS-D12 mAb

    MERS-D12; MERS antibody-D12

    		 SARS-CoV Infection
    Anti-MERS-D12 mAb (MERS-D12; MERS Antibody-D12) is a human monoclonal IgG1. Anti-MERS-D12 mAb binds directly to the DPP4 interacting region of the MERS-CoV Spike receptor binding domain (RBD) and effect neutralization by directly blocking receptor binding .
    Anti-MERS-D12 mAb
  • HY-P99626
    Frovocimab

    LY 3015014

    		 PCSK9 Metabolic Disease
    Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody (mAb) that neutralizes PCSK9. Frovocimab inhibits PCSK9 binding to LDL receptor (LDLR) while permitting the normal proteolytic cleavage of the bound intact PCSK9 .
    Frovocimab
  • HY-P99671
    Isecarosmab

    M-6495

    		 ADAMTS Inflammation/Immunology
    Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
    Isecarosmab
  • HY-P99516
    Vulinacimab

    HLX-06

    		 VEGFR Cancer
    Vulinacimab (HLX-06) is an anti-VEGFR-2 monoclonal antibody (mAb). Vulinacimab can be used in the research of cancers. VEGFR-2, overexpressed in certain tumors, is critical in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells .
    Vulinacimab
  • HY-P9807
    Anti-SARS-CoV-2 Spike mAb (CR3022)

    SARS-CR3022; SARS-CoV-2 antibody-CR3022

    		 SARS-CoV Infection Inflammation/Immunology
    Anti-SARS-CoV-2 Spike mAb (CR3022) is a a CHO cell derived human monoclonal IgG1 antibody. It binds to both S1 domain of SARS-CoV/SARS-CoV-2 Spike protein .
    Anti-SARS-CoV-2 Spike mAb (CR3022)
  • HY-132158
    MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin

    		Drug-Linker Conjugates for ADC Cancer
    MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin (compound 21a), a camptothecin payload, can be conjugated to a monoclonal antibody (mAb) for the synthesis of camptothecin antibody-drug conjugate (ADC) .
    MC-AAA-NHCH2OCH2COO-7-aminomethyl-10-methyl-11-fluoro camptothecin
  • HY-P99253
    Mogamulizumab

    KW-0761

    		 CCR Inflammation/Immunology Cancer
    Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .
    Mogamulizumab
  • HY-P99172
    CC-90002

    		CD47 Interleukin Related Cancer
    CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar Kd value. CC-90002 can be used for the research of hematologic malignancies and solid tumors .
    CC-90002
  • HY-P99258
    Brontictuzumab

    OMP 52M51; Anti-Human NOTCH1 Recombinant antibody

    		 Notch Cancer
    Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma .
    Brontictuzumab
  • HY-P99114
    Sugemalimab

    		PD-1/PD-L1 Cancer
    Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .
    Sugemalimab
  • HY-P99351
    Andecaliximab

    Anti-MMP9 Reference antibody (andecaliximab)

    		 MMP Cancer
    Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) .
    Andecaliximab
  • HY-P99297
    Bedinvetmab

    ZTS-00508841

    		 Trk Receptor Inflammation/Immunology
    Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
    Bedinvetmab
  • HY-P99344
    Bamlanivimab

    Anti-Human SARS-CoV-2

    		 SARS-CoV Infection
    Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab .
    Bamlanivimab
  • HY-P99252
    Itolizumab

    Anti-Human CD6 Recombinant antibody

    		 CD6 Infection Inflammation/Immunology
    Itolizumab (Anti-Human CD6 Recombinant Antibody) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis (RA), COVID-19 .
    Itolizumab
  • HY-131081
    γ-Amanitin

    		DNA/RNA Synthesis ADC Cytotoxin Cancer
    γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits RNA polymerase II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin. γ-Amanitin competitively binds to monoclonal antibody (mAb), with an IC50 of 163.1 ng/mL .
    γ-Amanitin
  • HY-P99406
    Petosemtamab

    MCLA 158

    		 EGFR Cancer
    Petosemtamab (MCLA 158) is an anti- EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .
    Petosemtamab
  • HY-E70364
    IgdE protease

    		Biochemical Assay Reagents Inflammation/Immunology
    IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .
    IgdE protease
  • HY-P99259
    Cabiralizumab

    FPA 008; Anti-Human CSF1R Recombinant antibody

    		 c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
    Cabiralizumab
  • HY-P99325
    Toralizumab

    IDEC-131; Anti-Human CD40 ligand Recombinant antibody

    		 TNF Receptor Inflammation/Immunology
    Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research .
    Toralizumab
  • HY-P99385
    Vobarilizumab

    ALX-0061

    		 Interleukin Related Inflammation/Immunology
    Vobarilizumab (ALX-0061) is a humanized bispecific anti-IL-6R and anti-human serum albumin (ALB) monoclonal antibody (mAb) (Kd: 0.19 pM). Vobarilizumab consists of an anti-IL-6R domain and an anti-human serum albumin domain. Vobarilizumab can be used in the research of inflammatory autoimmune diseases, such as rheumatoid arthritis .
    Vobarilizumab
  • HY-P99340
    Sotrovimab
    1 Publications Verification

    VIR 7831

    		 SARS-CoV Infection Cancer
    Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
    Sotrovimab
  • HY-P99406A
    Petosemtamab (FUT8-KO)

    		EGFR Cancer
    Petosemtamab (FUT8-KO) is a knockout version of petosemtamab for the fucosyltransferase 8 gene (FUT8). Petosemtamab (HY-P99406) is an anti-EGFR (Kd: 0.22 nM) and anti-LGR5 (Kd: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to blockade of EGFR signaling and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the study of solid tumors such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC), etc .
    Petosemtamab (FUT8-KO)
  • HY-P99938
    Pucotenlimab

    HX008

    		 PD-1/PD-L1 Cancer
    Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti programmed cell death protein 1 (anti-PD-1) monoclonal antibody. Pucotenlimab can be used for the research of tumor .
    Pucotenlimab
  • HY-P9971
    Camrelizumab
    3 Publications Verification

    SHR-1210

    		 PD-1/PD-L1 Cancer
    Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
    Camrelizumab
  • HY-D1056A3
    Lipopolysaccharides, from E. coli O26:B6

    LPS, from Escherichia coli (O26:B6)

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Lipopolysaccharides, from E. coli O26:B6 is a lipopolysaccharide endotoxin and TLR-4 activator that activates the disease-related molecular pattern (PAMP) of the immune system and induces cell secretion of migratory bodies. Lipopolysaccharides, from E. coli O26:B6 consists of an antigen-specific O-chain, some cells lack an O-antigen-side chain, and is recognized by the core-specific monoclonal antibody MAb J8-4C10 .
    Lipopolysaccharides, from E. coli O26:B6
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: